Резюме The treatment of choice for patients with EGFR mutation-positive non-small cell
lung cancer (NSCLC) is an EGFR tyrosine kinase inhibitor (TKI). Most clinical trial data with …

The treatment of choice for patients with EGFR mutation-positive non-small cell lung cancer
(NSCLC) is an EGFR tyrosine kinase inhibitor (TKI). Most clinical trial data with these agents …

Opinion statement EGFR tyrosine kinase inhibitors (TKI) should always be considered when
treating advanced/metastatic non-small cell lung cancer (NSCLC) with atypical EGFR …

PURPOSE Approximately 10% of patients with epidermal growth factor receptor (EGFR)
mutation–positive non–small-cell lung cancer (NSCLC) harbor uncommon mutations. Here …

Background Osimertinib is standard of care for EGFR-mutated non-small cell lung cancer
(NSCLC) patients. The efficacy of the drug in patients with mutations other than the common …

Around one-third of non-small-cell lung cancers (NSCLCs) are driven by mutations in EGFR.
The most common of these alterations (in 85% of patients) are exon 19 deletions and exon …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been
established as the standard first-line treatment for patients with previously untreated …

Introduction Lung adenocarcinomas account for approximately 40–50% of all NSCLC (Non-
Small Cell Lung Cancer) cases. In addition, lung adenocarcinomas can harbor several …

Lung cancer is the most common primary cancer of the lung and is responsible for the ever
increasing number of cancer-related deaths worldwide. 1 Especially in China, the burden of …

Introduction: The third-generation tyrosine kinase inhibitor (TKI) osimertinib is recommended
as first-line therapy for advanced non-small cell lung cancer (NSCLC) with epidermal growth …